
    
      Primary Objective The primary objective is to determine the overall response rate after
      treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid
      cancer.

      Secondary Objectives The secondary objectives are to describe the overall survival (OS) and
      progression-free survival (PFS) after treatment with abemaciclib in patients with anaplastic
      thyroid/undifferentiated thyroid cancer.Safety assessments of AE's will also be analysed
    
  